A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells.
Novel arylethynyltriazole acyclonucleosides were synthesized and assessed for their anticancer activity on drug-resistant pancreatic cancer MiaPaCa-2 cells. One lead compound was found to have much more potent apoptosis-related antiproliferative effects than gemcitabine, the current first-line treatment for pancreatic cancer. Further investigations showed that this active compound did not inhibit DNA synthesis, which means that it does not resemble gemcitabine and may involve a different mechanism of action.
Wang
Menghua
M
State Key Laboratory of Virology, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, PR China.
Xia
Yi
Y
Fan
Yuting
Y
Rocchi
Palma
P
Qu
Fanqi
F
Iovanna
Juan L
JL
Peng
Ling
L
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009705:Nucleosides / Q000737:chemistry* / Q000494:pharmacology*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D014230:Triazoles / Q000737:chemistry* / Q000494:pharmacology*; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D009705:Nucleosides; D014230:Triazoles; D003841:Deoxycytidine; D000093542:Gemcitabine